Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

Lumicera Health Services announced today it has secured a purchase agreement with Anda, Inc., an independent wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., for a lower-priced ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Navitus will remove Stelara from formulary on July 1, 2025. Stelara, the brand name of the drug ustekinumab, is a popular treatment for plaque psoriasis, psoriatic arthritis, ulcerative colitis ...

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

J&J said it is seeking a preliminary injunction for Samsung Bioepis' Stelara biosimilar over an unauthorized sublicense deal ...

J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...